ReviewMolecular therapy. Nucleic acids2025
Deep learning in next-generation vaccine development for infectious diseases.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Artificial intelligence-driven discovery of coumarin-based therapeutics: Revolutionizing target identification and validation.Pharmaceutical science advances · 2026Review
- Immunoinformatics-guided design of a conserved multi-epitope vaccine candidate against pathogenic human coronaviruses.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Enhanced YOLO-based framework and benchmarking for automated Plasmodium vivax detection.Parasitology research · 2026Article
- Review
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- Potential role of different animal models for the evaluation of bioactive compounds.Annals of medicine and surgery (2012) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of vaccine development was changed in the genomic era with the help of computer science. Computer-aided vaccine epitope selection has become a foundation of rational vaccine design. Similarly, artificial intelligence (AI) is quickly transforming the vaccine development landscape. Deep learning (DL), a subset of AI, is used in the landscape of vaccine development in terms of its algorithms, tools, and technologies. This review article discussed the developmental history of the modern era of vaccine development strategies using both immunoinformatics with DL models, identification strategies of T cell epitopes and B cell epitopes through immunoinformatics and DL models, vaccine constructs development strategies using linker and adjuvant, and characterization strategies of vaccine construct using bioinformatics and immunoinformatics. Similarly, the article discusses different tools and technologies, from epitope mapping and vaccine construct development to characterization. Again, it also highlighted recent paradigm shifts, DL-based strategies in vaccine development, and different DL-based tools used for epitope mapping and vaccine construct development. However, integrated frameworks connecting the bioinformatics and DL approaches are rapidly progressing, which are necessary for DL-assisted epitope prediction and the subsequent steps for vaccine development. DL-assisted vaccine development is rapid and cost-effective, changing the scenario of next-generation vaccine development very fast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.